Method for stimulating intestinal barrier integrity after non-natural birth
AssigneeN.V. Nutricia
InventorsJoachim SCHMITT, Günther BOEHM, Christopher BEERMANN
Life of this patent
Estimating the term…
Abstract
The present invention relates to methods for feeding and stimulating the health of infants delivered via caesarean section comprising administering long chain polyunsaturated fatty acids and/or nucleotides.
Claims12
A method for stimulating development of healthy intestinal flora in an infant delivered by caesarian section by increasing species diversity of the Bifidobacteria in the intestines of the infant, comprising feeding to an infant delivered by caesarian section and suffering from low intestinal Bifidobacteria counts and/or lacking adequate species diversity of Bifidobacteria, a composition comprising:
- (a) a Bifidobacteria consisting of Bifidobacterium breve;
- and
- (b) at least non-digestible galacto-oligosaccharides;
- wherein the composition is not human breast milk, and wherein the administration increases the amount of intestinal Bifidobacterium breve and other Bifidobacterium species.
The method according to claim 11, wherein the LC-PUFA is selected from the group consisting of eicosapentaenoic acid, docosahexaenoic acid and arachidonic acid.
The method according to claim 11, wherein the LC-PUFA content is 0.1 to 15 wt. % based on weight of total lipid in the composition.
A method for stimulating development of healthy intestinal flora in an infant delivered by caesarian section by increasing species diversity of the Bifidobacteria in the intestines of the infant, comprising:
- (a) identifying an infant delivered via caesarean section and suffering from low intestinal Bifidobacteria counts and/or lacking adequate species diversity of Bifidobacteria;
- and
- (b) feeding the infant, a composition comprising:
- (i) a Bifidobacterium consisting of Bifidobacterium breve, and
- (ii) at least non-digestible galacto-oligosaccharides;
- wherein the composition is not human breast milk, and wherein the administration increases the amount of intestinal Bifidobacterium breve and other Bifidobacterium species.
Dependencies are inferred from the claim text.